Bortezomib will enhance the degree or outcome of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Increased flibanserin adverse outcomes may arise if coadministered with a number of weak CYP3A4 inhibitors. Vital: The drug info on this webpage is meant to get instructional. It isn't a https://kuwanona23332.nizarblog.com/26909173/the-best-side-of-2